Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

BACKGROUND: Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs are attractive candidates for “repurposing” as anti-viral agents. H...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Pharmacol Toxicol
Main Authors: Ananthula, Hari Krishna, Parker, Scott, Touchette, Erin, Buller, R. Mark, Patel, Gopi, Kalman, Daniel, Salzer, Johanna S., Gallardo-Romero, Nadia, Olson, Victoria, Damon, Inger K., Moir-Savitz, Tessa, Sallans, Larry, Werner, Milton H., Sherwin, Catherine M., Desai, Pankaj B.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6278073/
https://ncbi.nlm.nih.gov/pubmed/30514402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-018-0270-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados